Background Infectious keratitis (IK) is a leading cause of corneal blindness globally. While treatment can limit infection-related complications, the timeline and predictors of visual recovery in IK ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...

The medical board examining Imran Khan reported that his unaided vision is 6/24 in the right eye and 6/9 in the left eye. These numbers refer to visual acuity, which measures how clearly a person can ...

Analysis of the final APEX Phase 1b clinical results obtained with KSI-101 (Kodiak Sciences Inc.) evaluated to treat macular edema secondary to inflammation (MESI) showed that at week 24 well over ...

Srinivas Akkaraju, a director and ten percent owner of Kalaris Therapeutics, is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP, and Samsara Opportunity Fund GP, LLC ...

The U.S. Food and Drug Administration has approved Yuvezzi (carbachol and brimonidine tartrate) ophthalmic solution 2.75%/0.1 ...

Only those with excellent observation skills can find the hidden koala among the pandas in this optical illusion image. Can ...

What if eyesight were more than a measure of visual acuity — and instead a reflection of how the body, mind and spirit function together? Integrative optometrist Elisa Beth Haransky-Beck, OD, explores ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...

In a safety and feasibility trial of a cortical visual prosthesis, researchers observed progressive recovery of natural vision in a patient with complete blindness caused by irreversible optic nerve ...

Ray Therapeutics, a clinical-stage biotechnology company developing optogenetic gene therapies for vision restoration, today ...